menu
    • menu
    [{"orgOrder":0,"company":"Glycotope","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"DS-3939","moa":"||TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycotope \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Glycotope \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Glycotope","sponsor":"Byondis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Inapplicable","moa":"||GlycoTarget","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycotope \/ Byondis","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ Byondis"},{"orgOrder":0,"company":"Glycotope","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycotope \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ Evotec"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycotope \/ LegoChem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Glycotope","sponsor":"Therabest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GT-00AxIL15","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ Glycotope","highestDevelopmentStatusID":"4","companyTruncated":"Glycotope \/ Glycotope"},{"orgOrder":0,"company":"Glycotope","sponsor":"PentixaPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"||Lewis Y","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ PentixaPharm","highestDevelopmentStatusID":"4","companyTruncated":"Glycotope \/ PentixaPharm"},{"orgOrder":0,"company":"Glycotope","sponsor":"Max Delbr\u00fcck Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ Max Delbr\u00fcck Center","highestDevelopmentStatusID":"4","companyTruncated":"Glycotope \/ Max Delbr\u00fcck Center"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"GT-00X","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ Glycotope","highestDevelopmentStatusID":"2","companyTruncated":"Glycotope \/ Glycotope"}]

    Find Clinical Drug Pipeline Developments & Deals by Glycotope

    Menu

    Glycotope

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-3939,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Daiichi Sankyo

                            Deal Size : $132.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP Rights from Glycotope

                            Details : Daiichi acquires the TA-MUC1 antibody, gatipotuzumab to advance the clinical development of DS-3939. It is being evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : DS-3939,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Daiichi Sankyo

                            Deal Size : $132.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT-001,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : PentixaPharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pentixapharm Acquires Target Discovery Business of Glycotope

                            Details : Through the acquisition, Pentixapharm will leverage the Glycotype portfolio of preclinical antibodies against multiple oncology including GT-001, which is being evaluated for breast and lung cancer.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            March 07, 2024

                            Lead Product(s) : GT-001,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : PentixaPharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Glycotope and Evotec Enter Licensing Agreement to Combine Glycotope Antibodies and Evotec’s Immune Cell Enga...

                            Details : The agreement aims to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 12, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : LegoChem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Developme...

                            Details : The agreement aims to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies. LCB has worldwide exclusive rights to develop and commercialize the selected antibody as an ADC...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : LegoChem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Max Delbrück Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Glycotope and Max Delbrück Center Enter into Research Collaboration to Explore Combination of GlycoTargets an...

                            Details : The collaboration aims to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 25, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Max Delbrück Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TB-100,GT-00AxIL15

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Therabest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therabest and Glycotope to Assess Therabest’s iPSC-derived NK Cell Product TB-100 in Combination with Glycot...

                            Details : The combination of Therabest’s iPSC derived NK cell therapy TB-100 and Glycotope’s tumor-targeted immuno-cytokine GT-00AxIL15 challenges the current NK cell therapy paradigm by converging a two-component platform improves the activity of TB-100.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            December 13, 2022

                            Lead Product(s) : TB-100,GT-00AxIL15

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Therabest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT-00X,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : LegoChem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for u...

                            Details : Glycotope’s antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GT-00X). Targeting these specific antigens enables broad indication range, long-term treatment potential and reduced on-tar...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : GT-00X,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : LegoChem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Byondis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Byondis , Glycotope Enter Platform Access Agreement Discovery and Development

                            Details : Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclose...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 27, 2021

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Byondis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gatipotuzumab,Tomuzotuximab,Cetuximab,Panitumumab,Necitumumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 04, 2017

                            Lead Product(s) : Gatipotuzumab,Tomuzotuximab,Cetuximab,Panitumumab,Necitumumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab,Cisplatin,Carboplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CetuGEXâ„¢ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer

                            Details : Undisclosed

                            Product Name : CetuGEX

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 03, 2014

                            Lead Product(s) : Cetuximab,Cisplatin,Carboplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth